We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1501
CTS Corp
CTS
$1.84B
| $811K | ﹤0.01% |
23,805
-4,954
| -17% | -$180K |
|
|
CIM
1502
Chimera Investment
CIM
$1B
| $809K | ﹤0.01% |
30,579
-20,652
| -40% | -$612K |
|
1503
Omnicell
OMCL
$1.69B
| $808K | ﹤0.01% |
7,106
-6,106
| -46% | -$701K |
|
1504
National Beverage
FIZZ
$2.89B
| $804K | ﹤0.01% |
16,421
-570
| -3% | -$26.6K |
|
|
AMED
1505
DELISTED
Amedisys
AMED
| $802K | ﹤0.01% |
7,627
+1,967
| +35% | +$251K |
|
1506
Cimpress
CMPR
$2.35B
| $802K | ﹤0.01% |
20,623
-9,813
| -32% | -$479K |
|
1507
Arbor Realty Trust
ABR
$1,000M
| $796K | ﹤0.01% |
60,755
+41,953
| +223% | +$674K |
|
1508
Cohen & Steers
CNS
$4.39B
| $795K | ﹤0.01% |
12,500
+859
| +7% | +$65K |
|
|
TBI
1509
Trueblue
TBI
$309M
| $795K | ﹤0.01% |
44,420
+31,847
| +253% | +$747K |
|
|
ROIC
1510
DELISTED
Retail Opportunity Investments Corp.
ROIC
| $795K | ﹤0.01% |
50,408
-9,455
| -16% | -$169K |
|
1511
Orthofix Medical
OFIX
$429M
| $794K | ﹤0.01% |
33,725
-17,470
| -34% | -$500K |
|
1512
Scorpio Tankers
STNG
$3.72B
| $793K | ﹤0.01% |
22,981
-5,176
| -18% | -$150K |
|
1513
Chord Energy
CHRD
$7.63B
| $790K | ﹤0.01% |
6,491
-3,179
| -33% | -$465K |
|
1514
OSI Systems
OSIS
$3.82B
| $790K | ﹤0.01% |
9,251
-668
| -7% | -$54.8K |
|
1515
Tidewater
TDW
$4.5B
| $790K | ﹤0.01% |
37,440
-5,414
| -13% | -$125K |
|
1516
World Kinect Corp
WKC
$1.92B
| $790K | ﹤0.01% |
38,610
-83,815
| -68% | -$2.06M |
|
1517
TriCo Bancshares
TCBK
$1.83B
| $788K | ﹤0.01% |
17,260
-10,837
| -39% | -$456K |
|
1518
Ormat Technologies
ORA
$7B
| $786K | ﹤0.01% |
10,035
+5,159
| +106% | +$407K |
|
1519
Amcor
AMCR
$21.8B
| $784K | ﹤0.01% |
12,670
+1,234
| +11% | +$76.3K |
|
|
NWLI
1520
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $783K | ﹤0.01% |
3,864
+264
| +7% | +$54K |
|
|
CFB
1521
DELISTED
CrossFirst Bankshares, Inc. Common Stock
CFB
| $777K | ﹤0.01% |
58,833
-1,995
| -3% | -$26.9K |
|
1522
MGP Ingredients
MGPI
$387M
| $774K | ﹤0.01% |
7,735
+175
| +2% | +$16.5K |
|
|
DHC
1523
Diversified Healthcare Trust
DHC
$2B
| $773K | ﹤0.01% |
424,658
+250,405
| +144% | +$572K |
|
1524
Atea Pharmaceuticals
AVIR
$403M
| $769K | ﹤0.01% |
108,297
-173,178
| -62% | -$1.18M |
|
1525
El Pollo Loco
LOCO
$451M
| $766K | ﹤0.01% |
77,796
+29,679
| +62% | +$312K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.